2017 / 01

Next Paper
DOI: 10.24075/brsmu.2017-01-04

ORIGINAL RESEARCH

Aminopyridine- and aminopyrimidine-based serine/threonine protein kinase inhibitors are drug candidates for treating drug-resistant tuberculosis

Maslov DA1, Bekker OB1, Alekseeva MG1, Kniazeva LM1, Mavletova DA1, Afanasyev II2, Vasilevich NI2, Danilenko VN
About authors

1 Laboratory of Bacterial Genetics, Department of Genetics and Biotechnology,
Vavilov Institute of General Genetics of RAS, Moscow, Russia

2 Novie Nauchnie Tekhnologii Ltd., Moscow, Russia

Correspondence should be addressed: Valery N. Danilenko
ul. Gubkina, d. 3, Moscow, Russia, 119991; ur.ggiv@direlav

About paper

Funding: this work was supported by the Ministry of Education and Science of the Russian Federation (Grant No. 14.576.21.0019 dated July 27, 2014; ID RFMEFI57614X0019).

Contribution of the authors to this work: Maslov DA — experiment planning, data collection, analysis and interpretation, drafting a manuscript; Bekker OB — experiment planning, data analysis and interpretation, drafting a manuscript; Alekseeva MG, Kniazeva LM, Mavletova DA — data collection, participation in drafting of a manuscript; Afanasyev II, Vasilevich NI — provision of compound under study, participation in drafting a manuscript; Danileno VN — experiment planning, data interpretation, participation in drafting of a manuscript.

Received: 2017-01-30 Accepted: 2017-02-11 Published online: 2017-03-13
|
  1. World Health Organization. Global Tuberculosis Report 2016. Geneva, Switzerland; 2016. p. 1–214.
  2. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, et al. Multidrug-resistant and extensively drug- resistant tuberculosis: a threat to global control of tuberculosis. The Lancet. 2010 May; 375 (9728): 1830–43.
  3. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis Elsevier; 2010 Sep; 10 (9): 621–9.
  4. Parida SK, Axelsson-Robertson R, Rao MV, Singh N, Master I, Lutckii A, et al. Totally drug-resistant tuberculosis and adjunct therapies. J Intern Med. 2015 Apr; 277 (4): 388–405.
  5. Klopper M, Warren RM, Hayes C, Gey van Pittius NC, Streicher EM, Müller B, et al. Emergence and Spread of Extensively and Totally Drug-Resistant Tuberculosis, South Africa. Emerging Infect Dis. 2013 Mar; 19 (3): 449–55.
  6. Velayati AA, Farnia P, Masjedi MR. The totally drug resistant tuberculosis (TDR-TB). Int J Clin Exp Med. 2013; 6 (4): 307–9.
  7. Prozorov AA, Zaichikova MV, Danilenko VN. [Mycobacterium tuberculosis mutants with multidrug resistance: History of origin, genetic and molecular mechanisms of resistance, and emerging challenges]. Russ J Genet. 2012 Jan 1; 48 (1): 1–14. Russian.
  8. Vareldzis BP, Grosset J, de Kantor I, Crofton J, Laszlo A, Felten M, et al. Drug-resistant tuberculosis: laboratory issues. World Health Organization recommendations. Tuber Lung Dis. 1994 Feb; 75 (1): 1–7.
  9. Kakkar AK, Dahiya N. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls. Tuberculosis. 2014 Jul; 94 (4): 357–62.
  10. Prozorov AA, Fedorova IA, Bekker OB, Danilenko VN. [The virulence factors of Mycobacterium tuberculosis: Genetic control, new conceptions]. Russ J Genet. 2014 Aug 1; 50 (8): 775–97. Russian.
  11. Forrellad MA, Klepp LI, Gioffré A, Sabio y García J, Morbidoni HR, la Paz Santangelo de M, et al. Virulence factors of the Mycobacterium tuberculosis complex. Virulence. 2013 Jan 1; 4 (1): 3–66.
  12. Danilenko VN, Osolodkin DI, Lakatosh SA, Preobrazhens- kaya MN, Shtil AA. Bacterial eukaryotic type serine-threonine protein kinases: from structural biology to targeted anti-infective drug design. Curr Top Med Chem. 2011; 11 (11): 1352–69.
  13. Cousin C, Derouiche A, Shi L, Pagot Y, Poncet S, Mijakovic I. Protein-serine/threonine/tyrosine kinases in bacterial signaling and regulation. FEMS Microbiol Lett. 2013 Sep; 346 (1): 11–9.
  14. Canova MJ, Molle V. Bacterial serine/threonine protein kinases in host-pathogen interactions. J Biol Chem. 2014 Apr 4; 289 (14): 9473–9.
  15. Seganish WM, Fischmann TO, Sherborne B, Matasi J, Lavey B,
  16. Bekker OB, Sokolov DN, Luzina OA, Komarova NI, Gatilov YV, Andreevskaya SN, et al. Synthesis and activity of (+)-usnic acid and (−)-usnic acid derivatives containing 1,3-thiazole cycle against Mycobacterium tuberculosis. Med Chem Res. 2015; 24: 2926.
  17. Maslov DA. Sozdanie test-sistemy dlya otbora ingibitorov serin- treoninovykh proteinkinaz mikobakteriy [dissertation]. Moscow: Vavilov Institute of General Genetics of RAS, 2016. Russian.
  18. Sizova IA, Hegemann P, Furmann M, Danilenko VN. Streptomyces rimosus Aminoglycoside 3“-Phosphotransferase VIII: Comparisons with Aminoglycoside 3-”Phosphotransferases of Aminoglycoside-Producing Strains and with Eukaryotic Protein Kinases. Molecular Biology. Kluwer Academic Publishers-Plenum Publishers; 2002; 36 (1): 18–25.
  19. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. 1989.
  20. Baki A, Bielik A, Molnár L, Szendrei G, Keserü GM. A High Throughput Luminescent Assay for Glycogen Synthase Kinase-3 βInhibitors. ASSAY and Drug Development Technologies. 2007 Feb; 5 (1): 75–84.
  21. Lunagariya MV, Thakor KP, Waghela BN, Vaidya FU, Pathak C, Patel MN. Design, synthesis, MTT assay, DNA interaction studies of platinum(II) complexes. J Biomol Struct Dyn. 2017 Jan 4: 1–18.
  22. Simonov AYu, Lakatosh SA, Luzikov YuN, Reznikova MI, Susova OYu, Shtil' AA, i dr. Sintez 4-zameshchennykh 3-[3-(dialkilaminometil)indol-1-il]maleinimidov i izuchenie ikh sposobnosti ingibirovat' proteinkinazu C-α, predotvrashchat' razvitie mnozhestvennoy lekarstvennoy ustoychivosti opukholevykh kletok i tsitotoksichnosti. Izvestiya Akademii nauk. Seriya khimicheskaya. 2008; (9): 1977–85. Russian.
  23. Bekker OB, Alekseeva MG, Osolodkin DI, Palyulin VA, Elizarov SM, Zefirov NS, et al. New Test System for Serine/ Threonine Protein Kinase Inhibitors Screening: E. coli APHVIII/ Pk25 design. Acta Naturae. Park Media; 2010 Jul; 2 (3): 110–21.
  24. Davis PD, Hill CH, Lawton G, Nixon JS, Wilkinson SE, Hurst SA, et al. Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan; 35 (1): 177–84.
  25. Coxon GD, Cooper CB, Gillespie SH, McHugh TD. Strategies and challenges involved in the discovery of new chemical entities during early-stage tuberculosis drug discovery. J. Infect. Dis. Oxford University Press; 2012 May 15;205 Suppl 2(suppl 2): S258–64.
  26. Andries K, Verhasselt P, Guillemont J, Göhlmann HWH, Neefs J-M, Winkler H, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science; 2005 Jan; 307 (5707): 223–227.
  27. Cooper CB. Development of Mycobacterium tuberculosis Whole Cell Screening Hits as Potential Antituberculosis Agents. J Med Chem: 2013 Oct 24; 56 (20): 7755–7760.